International Journal of Engineering Research

Open Access Open Access  Restricted Access Subscription Access

3D Printing in the Pharmaceutical and Biomedical Industries


Affiliations
1 Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India
2 Department of Polymer Science and Technology, Institute of Chemical Technology, Mumbai, India
3 Department of Dyestuff Technology, Institute of Chemical Technology, Mumbai, India
 

Additive manufacturing, also known as 3D printing, has the potential to transform manufacturing in pharmaceutical and biomedical industries. It is a highly customizable processing technique that can be applied to polymers and other bio-materials. These days 3D printing with novel materials has appealed to the industries as material have been designed to have synergistic properties. In the Pharmaceutical Industries, working with low quantities with accuracy, precise spatial control can be achieved by employing this technique, which allows us to prepare intricate compositions and 3D geometries are possible. With this technology, customization of dosage form is possible. As per the patient needs, the dosage form can be designed with multiple active pharmaceutical ingredients and desired release profiles. 3D printing also finds it applications in the Biomedical field, as it offers great precision and control of the internal architecture and complicated structures found in biological tissues and organs. Advances in past few years have assisted 3D printing of biocompatible polymers and supporting components into complex 3D functional biological tissues scaffolds and living organs. The adaptability of interactions enables the more simplistic manufacturing of complex parts with tailored structures. The potential for polymers to generate well-defined parts, tissues scaffolds, and complex compositions for drug delivery provides an unparalleled route for developing next-generation 3D printed materials having applicability in the pharmaceutical and biomedical industry.

Keywords

3D Printing, Biocompatible Polymers, Drug Delivery, Artificial Organs.
User
Notifications
Font Size

  • i. Rapid Prototyping of Biomaterials - 1st Edition [WWW Document], n.d. URL https://www.elsevier.com/books/rapid-prototyping-of-biomaterials/narayan/978-0-85709-599-2 (accessed 10.7.17).

  • ii. Continuous 3D-printing for additive manufacturing | Rapid Prototyping Journal | Vol 20, No 4 [WWW Document], n.d. URL http://www.emeraldinsight.com/doi/abs/10.1108/RPJ-08-2012-0068 (accessed 10.7.17).

  • iii. Schubert C., van Langeveld MC., Donoso LA.,: Innovations in 3D printing: a 3D overview from optics to organs. Br J Ophthalmol 2014; 98: 159–161.

  • iv. Klein GT., Lu Y., Wang MY.: 3D printing and neurosurgery ready for prime time? World Neurosurg 2013; 80: 233–235.

  • v. Daly R., Harrington TS., Martin GD., Hutchings IM.: Inkjet printing for pharmaceutics - A review of research and manufacturing. Int J Pharm 2015; 494: 554–567.

  • vi. Rowe CW, Katstra WE, Palazzolo RD, et al. Multimechanism oral dosage forms fabricated by three dimensional printing. J Control Release 2000;66:11–7.

  • vii. Moulton SE, Wallace GG. 3-Dimensional (3D) fabricated polymer based drug delivery systems. J Control Release 2014; 193:27–34.

  • viii. Alomari M, Mohamed FH, Basit AW, Gaisford S. Personalised dosing: printing a dose of one’s own medicine. Int J Pharm 2015;494:568–77.

  • ix. Katstra WE, Palazzolo RD, Rowe CW, et al. Oral dosage forms fabricated by three dimensional printing. J Control Release 2000;66:1–9.

  • x. Banks J. Adding value in additive manufacturing: Researchers in the United Kingdom and Europe look to 3D printing for customization. IEEE Pulse. 2013;4(6):22–26.

  • xi. Mertz L. Dream it, design it, print it in 3-D: What can 3-D printing do for you? IEEE Pulse. 2013;4(6):15–21.

  • xii. Ursan I, Chiu L, Pierce A. Three-dimensional drug printing: a structured review. J Am Pharm Assoc. 2013;53(2):136–144.

  • xiii. Gross BC, Erkal JL, Lockwood SY, et al. Evaluation of 3D printing and its potential impact on biotechnology and the chemical sciences. Anal Chem. 2014;86(7):3240–3253.

  • xiv. Bartlett S. Printing organs on demand. Lancet Respir Med. 2013;1(9):684.

  • xv. Di Prima, M., Coburn, J., Hwang, D., Kelly J., Khairuzzaman, A., and Ricles, L. Additively manufactured medical products—the FDA perspective. 3D Print Med 2, 1, 2016.

  • xvi. Stansbury, J.W., Idacavage, M.J., 2016. 3D printing with polymers: Challenges among expanding options and opportunities. Dental Materials 32, 54–64. doi:10.1016/j.dental.2015.09.018

  • xvii. Gebhardt, A. Rapid Prototyping; Hanser Verlag: Munich, DE, 2003

  • xviii. Ligon, S.C., Liska, R., Stampfl, J., Gurr, M., Mülhaupt, R., 2017. Polymers for 3D Printing and Customized Additive Manufacturing. Chem. Rev. 117, 10212–10290. doi:10.1021/acs.chemrev.7b00074

  • xix. Wu, B. M.; Borland, S. W.; Giordano, R. A.; Cima, L. G.; Sachs, E. M.; Cima, M. J. Solid Free-Form Fabrication of Drug Delivery Devices. J. Controlled Release 1996, 40, 77−87.

  • xx. Goyanes, A.; Buanz, A. B. M.; Basit, A. W.; Gaisford, S. FusedFilament 3D Printing (3DP) for Fabrication of Tablets. Int. J. Pharm. 2014, 476, 88−92.

  • xxi. Goyanes, A.; Buanz, A. B. M.; Hatton, G. B.; Gaisford, S.; Basit, A. W. 3D Printing of Modified-Release Aminosalicylate (4-ASA and 5ASA) Tablets. Eur. J. Pharm. Biopharm. 2015, 89, 157−162.

  • xxii. Goyanes, A.; Chang, H.; Sedough, D.; Hatton, G. B.; Wang, J.; Buanz, A.; Gaisford, S.; Basit, A. W. Fabrication of Controlled-Release Budesonide Tablets via Desktop (FDM) 3D Printing. Int. J. Pharm. 2015, 496, 414−420.

  • xxiii. Goyanes, A.; Kobayashi, M.; Martinez-Pacheco, R.; Gaisford, S.; Basit, A. W. Fused-Filament 3D Printing of Drug Products: Microstructure Analysis and Drug Release Characteristics of Pva-Based Caplets. Int. J. Pharm. 2016, 514, 290−295.

  • xxiv. Goyanes, A.; Wang, J.; Buanz, A.; Gaisford, S.; Basit, A. W.; Goyanes, A.; Martinez-Pacheco, R.; Telford, R.; Gaisford, S.; Basit, A. W. 3D Printing of Medicines: Engineering Novel Oral Devices with Unique Design and Drug Release Characteristics. Mol. Pharmaceutics 2015, 12, 4077−84.

  • xxv. Skowyra, J.; Pietrzak, K.; Alhnan, M. A. Fabrication of Extended-Release Patient-Tailored Prednisolone Tablets via Fused Deposition Modelling (FDM) 3D Printing. Eur. J. Pharm. Sci. 2015, 68, 11−17.

  • xxvi. Genina, N.; Hollander, J.; Jukarainen, H.; Makila, E.; Salonen, J.; Sandler, N. Ethylene Vinyl Acetate (EVA) as a New Drug Carrier for 3D Printed Medical Drug Delivery Devices. Eur. J. Pharm. Sci. 2016, 90, 53−63.

  • xxvii. Hollander, J.; Genina, N.; Jukarainen, H.; Khajeheian, M.; Rosling, A.; Makila, E.; Sandler, N. Three-Dimensional Printed PCLBased Implantable Prototypes of Medical Devices for Controlled Drug Delivery. J. Pharm. Sci. 2016, 105, 2665−2676.

  • xxviii. Alhijjaj, M.; Belton, P.; Qi, S. An Investigation into the Use of Polymer Blends to Improve the Printability of and Regulate Drug Release from Pharmaceutical Solid Dispersions Prepared via Fused Deposition Modeling (FDM) 3D Printing. Eur. J. Pharm. Biopharm. 2016, 108, 111−125.

  • xxix. Okwuosa, T. C.; Pereira, B. C.; Arafat, B.; Cieszynska, M.; Isreb, A.; Alhnan, M. A. Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy. Pharm. Res. 2017, 34, 427−437.

  • xxx. Goyanes, A.; Robles, M. P.; Buanz, A.; Basit, A. W.; Gaisford, S. Effect of Geometry on Drug Release from 3D Printed Tablets. Int. J. Pharm. 2015, 494, 657−63.

  • xxxi. Wang, J.; Goyanes, A.; Gaisford, S.; Basit, A. W. Stereolithographic (SLA) 3D Printing of Oral Modified-Release Dosage Forms. Int. J. Pharm. 2016, 503, 207−212.

  • xxxii. Pardo, L.; Wilson, W. C.; Boland, T. Characterization of Patterned Self-Assembled Monolayers and Protein Arrays Generated by the Ink-Jet Method. Langmuir 2003, 19, 1462−1466.

  • xxxiii. Mironov, V.; Boland, T.; Trusk, T.; Forgacs, G.; Markwald, R. R. Organ Printing: Computer-Aided Jet-Based 3D Tissue Engineering. Trends Biotechnol. 2003, 21, 157−161.

  • xxxiv. Gebler M, Uiterkamp A, Visser C. A global sustainabilityperspective on 3D printing technologies. Energy Policy2014;74:158–67.

  • xxxv. Weller C, Kleer R, Piller FT. Economic implications of 3Dprinting: market structure models in light of additivemanufacturing revisited. Int J Prod Econ 2015;164:43–56.


Abstract Views: 301

PDF Views: 0




  • 3D Printing in the Pharmaceutical and Biomedical Industries

Abstract Views: 301  |  PDF Views: 0

Authors

Ameya Chaudhari
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India
Jay Patel
Department of Polymer Science and Technology, Institute of Chemical Technology, Mumbai, India
Suyash Oka
Department of Dyestuff Technology, Institute of Chemical Technology, Mumbai, India
Manish Jain
Department of Dyestuff Technology, Institute of Chemical Technology, Mumbai, India

Abstract


Additive manufacturing, also known as 3D printing, has the potential to transform manufacturing in pharmaceutical and biomedical industries. It is a highly customizable processing technique that can be applied to polymers and other bio-materials. These days 3D printing with novel materials has appealed to the industries as material have been designed to have synergistic properties. In the Pharmaceutical Industries, working with low quantities with accuracy, precise spatial control can be achieved by employing this technique, which allows us to prepare intricate compositions and 3D geometries are possible. With this technology, customization of dosage form is possible. As per the patient needs, the dosage form can be designed with multiple active pharmaceutical ingredients and desired release profiles. 3D printing also finds it applications in the Biomedical field, as it offers great precision and control of the internal architecture and complicated structures found in biological tissues and organs. Advances in past few years have assisted 3D printing of biocompatible polymers and supporting components into complex 3D functional biological tissues scaffolds and living organs. The adaptability of interactions enables the more simplistic manufacturing of complex parts with tailored structures. The potential for polymers to generate well-defined parts, tissues scaffolds, and complex compositions for drug delivery provides an unparalleled route for developing next-generation 3D printed materials having applicability in the pharmaceutical and biomedical industry.

Keywords


3D Printing, Biocompatible Polymers, Drug Delivery, Artificial Organs.

References